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Progress toward understanding Zika virus (ZIKV)
pathogenesis is hindered by lack of immunocom-
petent small animal models, in part because ZIKV
fails to effectively antagonize Stat2-dependent
interferon (IFN) responses in mice. To address
this limitation, we first passaged an African ZIKV
strain (ZIKV-Dak-41525) through Rag1/ mice to
obtain a mouse-adapted virus (ZIKV-Dak-MA) that
was more virulent than ZIKV-Dak-41525 in mice
treated with an anti-Ifnar1 antibody. A G18R substi-
tution in NS4B was the genetic basis for the
increased replication, and resulted in decreased
IFN-b production, diminished IFN-stimulated gene
expression, and the greater brain infection
observed with ZIKV-Dak-MA. To generate a fully
immunocompetent mouse model of ZIKV infection,
human STAT2 was introduced into the mouse
Stat2 locus (hSTAT2 KI). Subcutaneous inoculation
of pregnant hSTAT2 KI mice with ZIKV-Dak-MA
resulted in spread to the placenta and fetal brain.
An immunocompetent mouse model of ZIKV infec-
tion may prove valuable for evaluating countermea-
sures to limit disease.672 Cell Host & Microbe 23, 672–685, May 9, 2018 ª 2018 Elsevier InINTRODUCTION
Zika virus (ZIKV) is a mosquito, sexually, and vertically trans-
mitted flavivirus in the Flaviviridae family and was isolated origi-
nally in 1947 from a febrile sentinel rhesus monkey in Uganda.
Historically, ZIKV caused a self-limiting febrile illness in about
20% of adults, with the remainder of infections being subclinical
(Weaver et al., 2016), and was understudied until an outbreak
in 2013–2014 in French Polynesia and an epidemic in Brazil in
2015–2016 (Cao-Lormeau et al., 2014; Heymann et al., 2016;
Marrs et al., 2016). The recent epidemics have been associated
with ZIKV congenital syndrome and microcephaly in fetuses of
infected mothers and Guillain-Barre´ syndrome in adults.
In the developing fetal brain, ZIKV preferentially infects
neocortical neuroepithelial and neuronal stem cells (NSCs).
ZIKV infection leads to apoptosis, reduced proliferation, and
transcriptional alterations (Li et al., 2016a; Onorati et al., 2016;
Wu et al., 2017), all of which result in cortical thinning and neuro-
developmental anomalies. ZIKV also has been detected in tis-
sues outside of the CNS, including the testis, epididymis, eyes,
and female reproductive tract organs (Govero et al., 2016; Jo-
guet et al., 2017; Ma et al., 2016; Miner et al., 2016). The basis
of ZIKV cellular tropism remains unknown, although expression
of phosphatidylserine receptors (Meertens et al., 2017; Richard
et al., 2017), Musashi proteins in neurons (Chavali et al., 2017),
and the ability to evade innate immune host defense pathways
correlate with infectivity.c.
The type I interferon (IFN) signaling pathway is a primary
response to RNA virus infections in mammals and is triggered
by RIG-I-like and Toll-like recognition receptors. The resultant
induction of type I (e.g., IFN-a and IFN-b) and type III (e.g.,
IFN-l) IFNs and engagement of their respective heterodimeric
receptors (IFNAR1/IFNAR2 and IFNLR1/IL10Rb) result in Janus
(Jak) and tyrosine (Tyk) kinase phosphorylation, dimerization,
and nuclear translocation of STAT1 and STAT2, and the produc-
tion of hundreds of antiviral and immunomodulatory IFN-stimu-
lated genes (ISGs). Although the ZIKV NS5 protein evades the
human IFN signaling response by binding to and degrading
STAT2, it is unable to bind efficiently to mouse Stat2 and thus
lacks the ability to antagonize the mouse IFN response (Bowen
et al., 2017; Grant et al., 2016; Kumar et al., 2016).
While existingmousemodels of ZIKV infection in adult animals
have provided insight into pathogenesis and disease outcome,
they have been performed principally in mice with genetic or
acquired deficiencies of IFN signaling (reviewed in Morrison
and Diamond, 2017). It has been challenging to infect adult
immunocompetent mice productively through a natural periph-
eral route; viral replication is readily aborted by the innate
immune response before systemic dissemination (Aliota et al.,
2016; Lazear et al., 2016). An immunocompetent mouse model
of ZIKV infection that more closely reflects the human disease
could improve our understanding of the pathogenesis of ZIKV
and the ensuing host immune response, and have greater utility
for evaluating vaccines and therapeutics. Here, we first gener-
ated a mouse-adapted strain of ZIKV with a key mutation in
the viral NS4B gene, which facilitated less induction of IFN-b
and greater replication in NSCs and the brains of mice. By
combining this adapted virus with a transgenic mouse that
replaces mouse Stat2 with human STAT2 and thus allows
evasion of IFN signaling cascades in infected cells, we created
an immunocompetent mouse model of ZIKV infection that al-
lowed for trans-placental transmission and fetal infection.
RESULTS
A Mouse-Adapted ZIKV Strain
Adult immunocompetent wild-type (WT) mice are resistant to
ZIKV infection (Lazear et al., 2016) in part because ZIKV cannot
efficiently antagonize mouse Stat2 and type I IFN signaling
(Grant et al., 2016; Kumar et al., 2016). In an attempt to overcome
this restriction, we passaged an African strain of ZIKV (Dakar
41525, Senegal, 1984; GenBank: KU955591.1) in C57BL/6
Rag1/ mice with an intact type I IFN response. As these
mice lack mature B and T cell responses, we hypothesized
that the sustained pressure of an innate immune response might
facilitate evolution of viral escape mutants against IFN. We
selected an African strain of ZIKV (ZIKV-Dak) because of its
greater pathogenicity in WT neonatal mice than Asian strains
(Lazear et al., 2016). We initially tested 4- to 6-week-old Rag1/
mice for susceptibility to ZIKV-Dak, and all mice succumbed
within 31 days of infection (Figure 1A). To adapt ZIKV-Dak,
virus-containing brain homogenates isolated from moribund
Rag1/ mice were used for subcutaneous infection of naive
Rag1/ mice (Figure 1B). After four passages in Rag1/
mice, we inoculated this mouse-adapted virus (ZIKV-Dak-MA)
into 4- to 5-week-old WT mice after treatment with 2 mg anti-Ifnar1 monoclonal antibody (mAb) and compared it with the
parental virus. Anti-Ifnar1-treatedWTmiceweremore vulnerable
to infection with ZIKV-Dak-MA than ZIKV-Dak with a shorter time
to death (Figure 1C). We investigated the basis for increased
lethality by comparing viral RNA levels in serum, spleen, and
the brain at 3 and 6 days after subcutaneous inoculation
with 105 focus-forming units (FFU) of ZIKV-Dak or ZIKV-Dak-
MA. In serum, no difference was observed at day 3 between
the strains, whereas a slightly higher level was measured at
day 6 in ZIKV-Dak-MA-infected animals (Figure 1D). No differ-
ence in ZIKV-Dak and ZIKV-Dak-MA levels was detected in the
spleen at days 3 or 6 after infection (Figure 1E). However, we
observed higher levels of infection in the brains of ZIKV-Dak-
MA than ZIKV-Dak-infected mice on day 6 (Figure 1F). Thus,
ZIKV-Dak-MA replicated to moderately higher levels in the brain
of anti-Ifnar1-treated mice, and this phenotype was associated
with an increase in lethality.
To determine the genetic basis for the increased pathogenicity
of ZIKV-Dak-MA in mice, we performed next-generation
sequencing of the parental and adapted viruses. This analysis
revealed three mutations in greater than 95% of the ZIKV-Dak-
MA population (Figure 1G): a synonymous C to T change at
nucleotide 1,006, a non-synonymous A to G change at nucleo-
tide 5,808 resulting in a conservative lysine to arginine substitu-
tion at amino acid position 399 in NS3, and a non-synonymous G
to A change at nucleotide 6,965 resulting in a non-conservative
glycine to arginine substitution at amino acid position 18 in
NS4B. Analysis of the viral sequences obtained from the earlier
sequential passages (P2 and P3) in Rag1/ mice revealed that
the mutations in NS4B arose during the second virus passage,
with the NS3 mutation arising during the fourth passage (Table
S1). These mutations in NS3 and NS4B in ZIKV-Dak-MA were
not present in any ZIKV sequences available in the VIPR (Virus
Pathogen Database and Analysis Resource) databases, but
were present in some related mosquito- and tick-transmitted fla-
viviruses (Figures S1A and S1B).
ZIKV-Dak-MA Replicates More Efficiently in the Brain
and in NSCs
The increased infectivity of ZIKV-Dak-MA in brain tissue could
reflect an enhanced ability to cross the blood-brain barrier or
an intrinsic ability to replicate more efficiently in neuronal cell
targets. To evaluate these possibilities, we inoculated 4- to
5-week-old WT C57BL/6 mice with 104 FFU ZIKV-Dak or ZIKV-
Dak-MA via an intracranial route (no anti-Ifnar1 mAb treatment)
and compared lethality and viral burden. Remarkably, the ani-
mals did not succumb to infection with either virus, suggesting
that the changes in ZIKV-Dak-MA were not sufficient to result
in lethal infection in immunocompetent mice (Figure 2A).
Although both strains replicated in different regions of the brains
of WT mice, ZIKV-Dak-MA accumulated to greater levels (Fig-
ures 2B–2E). At day 4, the midbrain of ZIKV-Dak-MA-infected
mice had higher viral RNA burden (Figure 2D) than ZIKV-Dak-
challenged mice. By day 6, multiple regions of the brain had
higher levels of ZIKV-Dak-MA than ZIKV-Dak RNA (brain stem,
cerebellum, midbrain, and cortex) (Figures 2B–2E). In contrast,
the olfactory bulb showed no differences (Figure 2F).
To corroborate the differential infectivity of ZIKV-Dak and
ZIKV-Dak-MA, we performed infection studies in cell culture.Cell Host & Microbe 23, 672–685, May 9, 2018 673
Figure 1. Generation of an Adapted ZIKV with Increased Lethality and CNS Viral Burden in Mice
(A) Four- to 6-week-old Rag1/ mice were inoculated subcutaneously with ZIKV-Dakar 41525 (ZIKV-Dak) (three experiments, n = 8).
(B) Scheme of in vivo passaging of ZIKV-Dak. Brain homogenates (106 plaque-forming units [PFU]) from Rag1/ mice that succumbed to infection were
inoculated subcutaneously into naive Rag1/ mice.
(C) Four- to 5-week-old WT C57BL/6 mice were treated with anti-Ifnar1 mAb 1 day prior to subcutaneous inoculation with 105 FFU ZIKV-Dak or ZIKV-Dak-MA
(three experiments, n = 15, log rank test; ***p < 0.001).
(D–F) ZIKV RNA levels in serum (D), spleen (E), and brain (F) of WT mice after treatment with anti-Ifnar1 mAb and subcutaneous inoculation of ZIKV-Dak or
ZIKV-Dak-MA (three experiments, n = 8–12, Mann-Whitney test; *p < 0.05). Solid lines are median values, and dotted lines denote the limit of detection of
the assay.
(G) RNA was isolated from ZIKV-Dak-MA and subjected to next-generation sequencing. Mutations present in over 95% of genomes are shown.
See also Table S1 and Figure S1.As ZIKV replicates efficiently in NSCs (Li et al., 2016b; McGrath
et al., 2017), we isolated these cells from the subventricular
zone of 4- to 6-week-old WT C57BL/6 mice and analyzed multi-
step (MOI of 0.01) and single-step (MOI of 1) viral growth kinetics.674 Cell Host & Microbe 23, 672–685, May 9, 2018ZIKV-Dak-MA replicated to higher levels than ZIKV-Dak at multi-
ple time points (Figures 2G and 2H). The increased yield of ZIKV-
Dak-MA was not due to greater cell survival, as ZIKV-Dak-MA
resulted in more, not less, cell death than ZIKV-Dak (Figure 2I).
Figure 2. Enhanced Infectivity in the CNS and
NSCs of ZIKV-Dak-Ma
(A) Four- to 5-week-old WT C57BL/6 mice (without
Ifnar1 blockade) were inoculated via intracranial
route with ZIKV-Dak or ZIKV-Dak-MA and moni-
tored for survival (three experiments, n = 7).
(B–F) ZIKV RNA levels in (B) brainstem, (C) cere-
bellum, (D) midbrain, (E) cortex, and (F) olfactory
bulb in WT mice at days 4 or 6 after intracranial
challenge with ZIKV-Dak or ZIKV-Dak-MA (three
experiments, n = 6–9, Mann-Whitney test; **p <
0.01). Solid lines aremedian values, and dotted lines
denote the limit of detection of the assay.
(G–I) Adult NSCs were inoculated at an MOI of 1
(H and I) or 0.01 (G) with ZIKV-Dak or ZIKV-Dak-MA.
Infectious titers were determined by focus-forming
assay (FFA). Viability of NSCs (I) was normalized to
uninfected control cells (three experiments per-
formed in duplicate). Mean values ± SEM. A two-
way and one-way ANOVA with multiple comparison
correction were for viral titers and cell viability,
respectively (*p < 0.05; **p < 0.01; ***p < 0.001).
(J–N) Viral RNA levels in the (J) brainstem, (K) cere-
bellum, (L) midbrain, (M) cortex, and (N) olfactory
bulb in congenic Ifnar1/ mice at days 2 and
day 4 after intracranial challenge with ZIKV-Dak or
ZIKV-Dak-MA (3 experiments, n = 8–13, Mann-
Whitney test; *p < 0.05; **p < 0.01). Solid lines are
median values, and dotted lines denote the limit of
detection of the assay.
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Figure 3. The NS4B G18R Mutation Is Required for Enhanced Mouse Lethality and Increased NSC Infection by ZIKV
(A) ZIKV-Dakar 41525 infectious cDNA clone.
(B) Four- to 5-week-old WT C57BL/6 mice were treated with anti-Ifnar1 mAb 1 day prior to subcutaneous inoculation with infectious clone derived WT ZIKV-
Dakar 41525 (ZIKV-Dak-WT), ZIKV-Dak NS3 K399R, ZIKV-Dak NS4B G18R, or ZIKV-Dak NS3 K399R + NS4B G18R (ZIKV-Dak DM) (three to four experiments,
n = 15–16, log rank test compared with ZIKV-Dak-WT; ZIKV-Dak DM and ZIKV-Dak NS4B G18R, p < 0.001; ZIKV-Dak NS3 K399R, p > 0.9).
(C–E) Viral burden in serum (C), spleen (D), and brain (E) at day 6 post-subcutaneous inoculation with ZIKV-Dak-WT, ZIKV-Dak-DM, ZIKV-Dak NS3 K399R, or
ZIKV-Dak NS4B G18R of 4- to 5-week-old WT mice after treatment with anti-Ifnar1 mAb (3 experiments, n = 12–14, one-way ANOVA with multiple comparisons
correction; *p < 0.05; **p < 0.01; ***p < 0.001).
(legend continued on next page)
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We hypothesized that, compared with the parental virus, ZIKV-
Dak-MA may have acquired an ability to evade a type I IFN
response in the brain. To test this hypothesis, we compared
infectivity of ZIKV-Dak and ZIKV-Dak-MA in different brain
regions after intracranial inoculation of Ifnar1/ mice. No differ-
ences in infection were observed between ZIKV-Dak and
ZIKV-Dak-MA in different brain regions at day 2 after infection
(Figures 2J–2N). By day 4 after infection, minimal differences
in viral RNA levels (<2-fold) were observed between ZIKV-
Dak and ZIKV-Dak-MA in different brain regions. Because
ZIKV-Dak-MA infection resulted in up to 9-fold greater viral titers
than ZIKV-Dak in different brain regions of WT mice (Figures 2B–
2E), in aggregate, these data suggest that themajority of the repli-
cation disparity betweenZIKV-Dak andZIKV-Dak-MA in the brain
is likely due to a differential ability to evade type I IFN responses.
However, there is a small difference in relative infectivity that
could reflect effects on type I IFN-independent host defenses.
The NS4B G18R Mutation Determines the Increased
Pathogenicity of ZIKV-Dak-MA
ZIKV-Dak-MA had three mutations present in over 95% of the
viral population, two of which (NS3 K399R and NS4B G18R)
were non-synonymous changes. To evaluate which mutations
were responsible for enhanced infection and disease, we engi-
neered isogenic viruses from a quadripartite infectious clone of
ZIKV-Dakar 41525 (Figure 3A; STAR Methods). We produced
WT and isogenic variants with mutations in NS3 K399R, NS4B
G18R, or NS3 K399R and NS4B G18R (DM). Four- to 5-week-
old WT mice were pretreated with anti-Ifnar1 mAb and chal-
lenged with 105 FFU of the isogenic viruses (Figure 3B). Approx-
imately 95% of mice succumbed to ZIKV-Dak NS4B G18R or
ZIKV-Dak DM, whereas only 5%of animals died after inoculation
with ZIKV-Dak WT or ZIKV-Dak NS3 K399R (Figure 3B). Thus,
the NS4B G18R mutation was necessary and sufficient for
enhanced virulence. Viral burden analysis at day 6 after inocula-
tion corroborated these findings. Although no differences were
observed in serum (Figure 3C), ZIKV-Dak NS4B G18R and
ZIKV-Dak DM replicated to slightly higher titers in the spleen
than ZIKV-Dak WT (Figure 3D). Moreover, in the brain, at
day 6, ZIKV-Dak NS4B G18R and ZIKV-Dak DM accumulated
to higher levels than ZIKV-Dak WT (Figure 3E). Consistent with
these results, ZIKV-Dak NS4B G18R and ZIKV-Dak DM pro-
duced higher viral yields in the supernatants of mouse and
human NSCs (Figures 3F–3H) and induced greater cell death
than ZIKV-Dak WT at 96 hr post-infection (Figure 3I).
To assess whether the adaptive mutations could enhance the
pathogenicity of other ZIKV strains, we generated isogenic
viruses using an infectious clone of a Brazilian ZIKV strain
(BeH819015) (Widman et al., 2017). Three-week-old WT
C57BL/6 mice were pretreated with 2 mg anti-Ifnar1 mAb and(F–I) Mouse NSCswere inoculated at anMOI of 0.01 (F) or 1 (G and I) with ZIKV-Da
cell viability assay (I). Human NSCswere inoculated with ZIKV-DakWT or ZIKV-Da
performed in duplicate). For (F)–(H), mean ± SEM is shown. Viral titer and cell via
**p < 0.01; ***p < 0.001; ****p<0.0001).
(J and K) Three-week-old WT mice were treated with anti-Ifnar1 1 day prior to su
NS3 K399R, or ZIKV-Bzl NS4B G18R and monitored for survival (J) and weight
omitted from the weight change data (K) (five experiments, n = 8–17). Survival and
multiple comparison correction, respectively (*p < 0.05; **p < 0.01; ***p < 0.001;inoculated subcutaneously with 105 FFU of the WT clone-
derived ZIKV from Brazil (ZIKV-Bzl WT), a single NS3 K399R
mutant (ZIKV-Bzl NS3 K399R), or a single NS4B G18R mutant
(ZIKV-Bzl NS4B G18R). A majority of animals inoculated with
ZIKV-Bzl NS4BG18R succumbed to infection, whereas those in-
fected with ZIKV-Bzl WT or ZIKV-Bzl NS3 K399R did not (Fig-
ure 3J). Moreover, ZIKV-Bzl NS4B G18R-infected animals lost
weight, whereas ZIKV-Bzl WT or ZIKV-Bzl NS3 K399R-infected
animals did not (Figure 3K).
Single-Cell RNA Sequencing of Infected and Uninfected
Murine NSCs
To begin to determine how the adaptive NS4B mutation in ZIKV
affected IFN responses, we first performed single-cell RNA
sequencing (RNA-seq) analysis on uninfected and ZIKV-Dak
WT-infectedmurine NSCs at 24 and 48 hr time points (Figure 4A).
We detected large transcriptional changes in the ZIKV-infected
NSCs compared with the uninfected cells, particularly by 48 hr
(Figures 4B and S2). As expected, many cells expressed NSC
markers, including Id3, Rpl32, Cdk4, Nes, and Sox2, which
confirmed their cellular identity (Figure 4C) (Dulken et al., 2017).
Clustering analysis partitioned transcriptionally similar cells from
all uninfected and infected samples into six groups (Figure 4D).
The clusters were then manually labeled based on which RNAs
were highly differential between clusters (e.g., cell cycle, ISGs,
and levels of ZIKV RNA) (Figure 4E). ZIKV-infected cells were
defined as having greater than 0.03% of viral transcripts relative
to total cellular transcripts (STAR Methods), and increased from
none (uninfected), to a minority of cells at 24 hr (9%), to a majority
of cells (67%) at 48 hr after infection (Figure 4F). ISGs were
increased in cells exposed to ZIKV (Figure S2), with some (e.g.,
Ifnb1) correlating with viral RNA and infection, and others (e.g.,
Isg15, Rsad2, and Cxcl10) expressed in both infected (ZIKV
RNA+) and uninfected (ZIKV RNA) NSCs (Figures 4E–4G). By
48 hr,most cells responded to type I IFN signals based on expres-
sion of Rsad2 and Isg15, but only a small fraction accumulated a
high level of Ifnb1 transcripts and these were among the most in-
fected ones. The highly ZIKV-infected cells were the sole pro-
ducers of pro-inflammatory chemokines, including Ccl5 and
Cxcl10. The overall IFN effect also manifested in cell cycle arrest,
as the majority of the cells at 48 hr were in G0/G1 phase, whereas
at 0 and 24 hr cells were equally distributed across G0/G1, G2/M,
and S cell-cycle phases (Figure 4D). This analysis illustrates the
utility of single-cell RNA-seq in determining the transcriptional
changes in uninfected and virus-infected cell populations.
ZIKV-Dak NS4B G18R Induces Less of a Type I IFN
Response
We next used our single-cell RNA-seq analysis to define tran-
scriptional differences between ZIKV-Dak WT and ZIKV-DakkWT, ZIKV-Dak DM, or ZIKV-Dak NS4BG18R and analyzed by FFA (F andG) or
k NS4BG18R (MOI of 0.1) and analyzed by plaque assay (H) (three experiments
bility were analyzed (ANOVA with multiple comparisons corrections; *p < 0.05;
bcutaneous inoculation with ZIKV-Brazil BeH819015 (ZIKV-Bzl-WT), ZIKV-Bzl
(K). The single animal that survived infection with ZIKV-Bzl NS4B G18R was
weight loss data were analyzed by the log rank test and two-way ANOVA with
****p < 0.0001).
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NS4B G18R-infected murine NSCs (Figure 5A). Large transcrip-
tional differences were found in cells infected with either ZIKV
strain at the 48 hr time point compared with uninfected cells
(Figures 5B and S2). ZIKV RNA was present in NSCs inoculated
with either ZIKV-Dak WT or ZIKV-Dak NS4B G18R, and the tran-
scriptional signatures clustered similarly (Figure 5C). Although
more ZIKV-Dak NS4B G18R RNA was detected at 24 and
48 hr after infection (Figure 5D), many ISGs (e.g., Ifit1, Ifitm3,
and Isg15) were induced at lower levels in ZIKV-Dak NS4B
G18R than ZIKV-Dak WT-infected NSCs (Figures 5E and S3A).
Single-cell RNA-seq allowed separate transcriptional interroga-
tion of the uninfected and ZIKV-infected NSC populations. At
24 and 48 hr, ISGs were induced at a higher level in uninfected
cells from the ZIKV-Dak WT group than the ZIKV-Dak NS4B
G18R group (Figures 5E and S3A); this suggested that the
ZIKV-Dak NS4B G18R might antagonize induction of the type I
IFN response more efficiently than the parental virus, which
would have its greatest effect in cells responding to, but not
infected with, ZIKV. At 24 and 48 hr, ISG levels also were higher
in the infected cell subset from the ZIKV-Dak WT compared with
ZIKV-Dak NS4B G18R group, although the differences were less
than in the uninfected cells (Figure S3B).
To begin to address whether ZIKV-Dak NS4B G18R antago-
nized type I IFN responses and induction of ISGs, we first as-
sessed the levels of IFN-b in the supernatant of ZIKV-Dak WT
and ZIKV-Dak NS4B G18R-infected murine NSCs. Despite
higher levels of infection (Figure 3G), less IFN-b was detected
in the supernatant of ZIKV-Dak NS4B G18R than ZIKV-Dak
WT-infected cells at 48 hr (Figure 5F). However, both RNA-seq
and qRT-PCR data failed to show differences in IFN-bmRNA in-
duction after ZIKV-Dak WT and ZIKV-Dak NS4B G18R infection
of NSCs (Figures 5E and 5G). The lack of significant changes in
the IFN-bmRNA levels in the context of decreased IFN-b protein
in the supernatant of ZIKV-Dak NS4B G18R-infected cells sug-
gests that the NS4B G18R mutation might contribute to an
IFN-b translational block. Inhibition of IFN-b protein translation
has been described as a ZIKV immune evasion mechanism in
human dendritic cells (Bowen et al., 2017), although the mecha-
nism currently remains unknown.
To assess whether adapted ZIKV modulates type I IFN
signaling responses, murine NSCs that were pretreated with
anti-Ifnar1 antibody or exogenous IFN-b were inoculated with
ZIKV-Dak WT or ZIKV-Dak NS4B G18R. The greater infectivity
phenotype seen with ZIKV-Dak NS4B G18R by viral yield assays
or antigen staining (Figures 5H and 5I) was lost after anti-Ifnar1
mAb treatment, with both viruses replicating equivalently in
NSCs lacking type I IFN signaling (Figure 5J); these data suggest
that differences in replication in NSCs between ZIKV-Dak WTFigure 4. Single-Cell RNA-Seq of NSCs after Infection with ZIKV-Dak
(A) Scheme for single-cell RNA-seq experiment: 100,000 NSCs (uninfected or 2
replicates and pooled, and subsequently 17,500 cells were subjected to microflu
(B) T-distributed stochastic neighbor embedding (tSNE) plots comparing uninfec
(C) Violin plots showing expression of NSC-specific markers and RLR-related ge
(D) tSNE plots of all conditions with cell type clusters identified with graph-based
after their most highly differential genes.
(E) Expression of a subset of ISGs and cell-cycle markers used to determine clu
(F) Expression of ZIKV RNA overlaid on the tSNE analysis from (B).
(G) Violin plots showing expression of selected ISGs in NSCs from all three cond
See also Figure S2.and ZIKV-Dak NS4B G18R are dependent on type I IFN
signaling. However, pretreatment of NSCs with IFN-b resulted
in equivalent restriction of ZIKV-Dak WT and ZIKV-Dak NS4B
G18R (Figure 5K). As theWT and adapted ZIKV strains produced
different amounts of IFN-b protein, showed infection differences
that were abolished by anti-Ifnar1 mAb treatment, yet were
equally sensitive to exogenous IFN-b pretreatment, the NS4B
G18R mutation in ZIKV likely acts through its ability to diminish
IFN-b levels that initiate the antiviral IFN signaling pathway in
infected NSCs.
An Immunocompetent Mouse Model of ZIKV Infection
Our experiments suggested that ZIKV-Dak-MA acquired an abil-
ity to minimize induction of type I IFN yet still remained sensitive
to the antiviral effects of exogenous or paracrine-derived IFN,
likely because of its inability to bind to and degrade mouse
Stat2 (Bowen et al., 2017; Grant et al., 2016; Kumar et al.,
2016; Tripathi et al., 2017). To overcome this limitation and
create a fully immunocompetent mouse model of ZIKV patho-
genesis, we inserted by homologous recombination a human
STAT2 allele into the mouse Stat2 locus but retained the mouse
Stat2 promoter: exon 1 and part of exon 2 were derived from the
mouse gene (promoter sequences), and the remainder of exon
2 and all of exons 3 through 24 were from the human gene
(coding sequences) (Figure 6A). Southern blotting and PCR
corroborated the correct integration (Figures 6B and 6C), and
western blotting of splenocytes from mice treated with poly(I:C)
confirmed the loss of mouse Stat2 and the expression of human
STAT2 (Figure 6D). ISG induction (e.g., Oas1, Irf7, and Ifnb) in
hSTAT2 knockin (KI) mice downstream of IFN signaling was es-
tablished by administration of poly(I:C) via intranasal route and
interrogation of lungs 6 hr later, and appeared equivalent to
that observed in WT mice (Figure 6E).
We investigated the pathogenic potential of ZIKV-Dak-MA in
hSTAT2 KI mice without IFN blockade. Three-week-old hSTAT2
KI mice were inoculated subcutaneously with ZIKV-Dak or
ZIKV-Dak-MA and monitored. Thirty percent of hSTAT2 KI
mice succumbed to lethal ZIKV-Dak-MA infection, whereas
none died after inoculation with parental ZIKV-Dak (Figure 6F).
Viral burden analysis revealed higher levels of ZIKV-Dak-MA
than ZIKV-Dak in the spleen and brain, but not in serum, at day
9 (Figures 6G–6I). We next tested if pregnant female hSTAT2
KI mice could transmit ZIKV efficiently to developing fetuses.
Eleven-week-old WT or hSTAT2 KI dams that had been mated
to WT or hSTAT2 KI sires, respectively (fetuses are homozygous
WT or STAT2 KI), were inoculated with ZIKV-Dak or ZIKV-
Dak-MA via subcutaneous route on embryonic day (E)6.5, and
maternal and fetal tissues were collected on E13.5. Higher levels4 or 48 hr after ZIKV-Dak WT infection) were collected from three technical
idic-based single-cell RNA-seq library generation and sequencing.
ted and ZIKV-Dak WT-infected cells.
nes in NSCs from all three conditions.
clustering. Clusters were manually named (e.g., cell cycle and IFN-responding)
sters of (D) overlaid on the tSNE analysis from (B).
itions.
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Figure 5. ZIKV-Dak NS4B G18R Induces Less IFN-b and Induction of ISGs in Infected NSCs
(A) Scheme of experiment: 100,000 NSCs (uninfected, 24 or 48 hr after ZIKV-Dak WT infection, or 24 or 48 hr after ZIKV-Dak NS4B G18R) were collected from
three technical replicates and pooled, and then 17,500 cells were subjected to microfluidic-based single-cell RNA-seq library generation and sequencing.
(B) tSNE plots comparing uninfected and ZIKV-Dak WT and ZIKV-Dak NS4B G18R-infected cells.
(C) Expression of ZIKV RNA overlaid on the tSNE plots from (B).
(D) Violin plots showing the expression of ZIKV viral RNA in all populations. Wilcoxon rank-sum test with continuity correction was performed (**p < 1010).
(legend continued on next page)
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of ZIKV-Dak-MA RNA were present in maternal serum and
spleen in hSTAT2 KI compared with WT dams (Figures 6J and
6K). ZIKV-Dak-MA infected the placenta and fetal head to
significantly higher levels in hSTAT2 KI compared with WT
mice (Figures 6L and 6M). Indeed, ZIKV RNA was detected in
the junctional layer of the placenta and uterine lining from
hSTAT2-infected dams (Figure S4). In comparison, hSTAT2 KI
dams infected with parental ZIKV-Dak had lower viral RNA levels
in maternal and fetal tissues (Figures S5A–S5E) than ZIKV-Dak-
MA-infected hSTAT2KI dams (Figures 6J–6M). Expression of the
human STAT2 allele for transmission was important for the dam,
as placentas and fetuses from hSTAT2 KI female mice mated to
WT males (fetuses are heterozygous for hSTAT2 allele) also
accumulated high levels of ZIKV (Figures S5F–S5J); these data
suggest that evasion of IFN signaling by ZIKV is necessary for
efficient dissemination of ZIKV to the maternal-fetal interface
but is largely dispensable for infection of the placenta and fetus.
Thus, by combining the adapted ZIKV strain with hSTAT2 KI
mice (Figure S5K), we generated lethality and placental trans-
mission models in immunocompetent mice after subcutaneous
inoculation.
DISCUSSION
ZIKV has emerged as an important global health concern due to
its teratogenic potential. With no currently approved vaccine or
treatment, there is an urgent need for the development of animal
models that recapitulate key features of human disease to un-
derstand the biology of this unique flavivirus and facilitate the
development of countermeasures. Here, we generated an
adapted ZIKV strain through passage in Rag1/ mice. This
strain had one critical mutation in the NS4B gene, which allowed
it to replicate to higher titers in NSCs and in the brains of mice,
and to some degree evade type I IFN responses. The NS4B
G18R substitution was necessary and sufficient to enhance the
pathogenicity of both African and Brazilian strains of ZIKV in
mice. Single-cell RNA-seq analysis of ZIKV-Dak- and ZIKV-
Dak-MA-infected NSCs revealed transcriptional changes be-
tween infected and uninfected cells and confirmed a reduced
type I IFN response in ZIKV-Dak-MA-infected cells. We com-
bined the pathogenic features of this adapted strain with hSTAT2
KI mice, which overcome the inherent inability of ZIKV strains to
bind and degrade mouse Stat2 (Bowen et al., 2017; Grant et al.,
2016; Kumar et al., 2016), to generate an immunocompetent
small animal model of ZIKV pathogenesis.
RNA viruses rapidly mutate to overcome selective immune or
drug pressures, gain host tropism, or acquire immune evasive(E) Violin plots were generated showing expression of selected RLRs (Ddx58, Ifih
Ifitm3, Isg15, Oasl1, Oasl2, and Rsad2) in uninfected (ZIKV RNA) and infected (
ZIKV-Dak NS4B G18R. MAST test was used to determine the statistical differen
(F) NSCs were inoculated with ZIKV-Dak WT and ZIKV-Dak NS4B G18R at an M
experiments in duplicate, mean ± SEM, Student’s t test; **p < 0.01).
(G) NSCs were inoculated with ZIKV-Dak WT and ZIKV-Dak NS4B G18R (MOI of
quantified by qRT-PCR. Expression was compared with uninfected cells (three e
(H–K) NSCs were untreated (no mAb) (H and I) or pretreated with anti-Ifnar1 block
or ZIKV-Dak NS4B G18R (MOI of 0.01). Infectious titers were determined by FFA.
cells were stained for ZIKV E protein and processed by flow cytometry.
The data in (G)–(K) are from three experiments in duplicate (G, H, J, and K,mean ± S
t test, **p < 0.01). See also Figures S2 and S3.functions. Several recent studies have identified mutations in
ZIKV that correlate with its epidemic emergence. One report
used phylogenetic analysis to predict positively selected muta-
tions in the N terminus (residue 26) and second ER loop (residues
87 and 88) of NS4B (Sironi et al., 2016), regions that inhibit type I
IFN responses and STING activity and also bind NS1 (Mun˜oz-
Jorda´n et al., 2005; Youn et al., 2012). A second study used an
evolutionary approach to identify two amino acid substitutions
in NS4B (V180I and L182S) present in epidemic strains (Zhu
et al., 2016). Neither of these studies identified the NS4B G18
residue as under strong positive selection, and indeed G18R
substitution is absent from all historical and circulating ZIKV
strains. Several explanations for this are possible, including
that residue 18 of NS4B is under strong purifying selection due
to compromising effects on virulence in the epidemic or enzootic
human, non-human primate, or mosquito hosts. Alternatively,
the substitution could be specific for certain hosts, which might
explain why some mosquito- and tick-borne flaviviruses with
other natural reservoirs (e.g., rodent or marsupial) have an
arginine at this position (Figure S1), and there is no selection
pressure to retain it in human/non-human primate/mosquito
transmission cycles.
The flavivirus NS4B protein contributes to remodeling of the
endoplasmic reticulum, which facilitates viral replication (Kaufusi
et al., 2014; Zmurko et al., 2015) and modulation of host defense
responses. Dengue virus NS4B inhibits IFN-a and -b induction by
altering mitochondrial morphology and RIG-I activation or by
inhibiting TBK1 and IRF3 activation (Chatel-Chaix et al., 2016;
Dalrymple et al., 2015). ZIKV NS4B also has been reported to
diminish innate immune responses by preventing or altering
activation of TBK1 (Onorati et al., 2016; Wu et al., 2017). Our
studies with ZIKV-Dak and ZIKV-Dak NS4B G18R in Ifnar1/
mice, anti-Ifnar1 mAb-treated NSCs, and IFN-b-pretreated
NSCs suggest that the adaptive substitution in NS4B does not
affect sensitivity to type I IFN or ISGs but rather affects IFN-b
induction. Our single-cell RNA-seq data in murine NSCs showed
decreased ISG induction in ZIKV-Dak NS4BG18R-infected cells
at 24 and 48 hr despite higher levels of intracellular viral RNA
and extracellular virus compared with ZIKV-Dak WT. Because
we distinguished transcriptional signatures of uninfected and
ZIKV-infected cells, we were able to observe that higher levels
of ISGs were induced in uninfected NSCs from the ZIKV-Dak
WT group compared with the ZIKV-Dak NS4B G18R group,
which likely rendered the uninfected cells in the ZIKV-Dak WT
group less permissive (Figure S3B). Our data are consistent
with a recent study in human dendritic cells showing that ZIKV
evades type I IFN immunity in part by diminishing translation of1, andMavs), type I IFNs (Ifna2 and Ifnb1), and ISGs (Eif2ak2, Ifit1, Ifit3, Ifitm2,
ZIKV RNA+) cells in the culture at 24 hr after inoculation with ZIKV-Dak WT or
ce in gene expression between different conditions (**p adjusted < 0.01).
OI of 1. Supernatant was collected and IFN-b was quantified by ELISA (three
1). Cells were lysed, RNA was isolated, and 18S, Ifnb1, and Isg15 mRNA was
xperiments in duplicate, Student’s t test for DDCt data).
ing mAb (J) or 3 U/mL IFN-b (K) for 16 hr and then inoculated with ZIKV-DakWT
In (I), NSCs were inoculated with ZIKV-Dak or ZIKV-Dak NS4B G18R. At 96 hr,
EM, two-way ANOVAwithmultiple comparison corrections; *p < 0.05; I, paired
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Figure 6. hSTAT2 KI Mice Are Susceptible to ZIKV-Dak-MA
(A) Diagram of targeting construct for hSTAT2 KI mice.
(B and C) Southern blot (B) and PCR (C) confirmation of integration of hSTAT2 allele.
(D) Western blot of hSTAT2 KI (h/h), WT (m/m), and Stat2/ (/) splenocytes from poly(I:C)-treated mice.
(E) ISG (Oas1, Irf7, and Ifnb) induction in WT and hSTAT2 KI mice after administration of poly(I:C) via an intranasal route and interrogation of lungs
6 hr later.
(F) Three-week-old hSTAT2 KI mice were inoculated subcutaneously with ZIKV-Dak or ZIKV-Dak-MA (three experiments; n = 12–26; log rank test, p = 0.06).
(G–I) Viral burden in serum (G), spleen (H), and brain (I) of 3-week-old hSTAT2 KI at day 9 after inoculation with ZIKV-Dak or ZIKV-Dak-MA (two experiments, n = 9,
Mann-Whitney test; **p < 0.01; ***p < 0.001). Solid lines are median values, and dotted lines denote the limit of detection of the assay.
(legend continued on next page)
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IFN-b protein (Bowen et al., 2017). Given that IFN-bmRNA levels
were similar in ZIKV-Dak-MA and ZIKV-Dak NS4B G18R-
infected cells, we speculate that the NS4B G18R mutation
may enhance the efficiency of a ZIKV-induced IFN-b transla-
tional block. The precise means by which changes in NS4B
sequence differentially affect IFN-b translation remain undeter-
mined, as the mechanism by which ZIKV diminishes translation
of IFN-b protein (Bowen et al., 2017) is unknown.
One caveat to our experiments with ZIKV-Dak and ZIKV-
Dak-MA is the relative disparity of phenotype between peripheral
organs and the brain after subcutaneous virus inoculation. As
many of these studieswere performed in anti-Ifnar1mAb-treated
mice, the differences in viral titers in peripheral organs (serum
and spleen) are small, as expected, between the WT and adapt-
ed ZIKV virus, analogous to our NSC experiments (Figure 5J). In
comparison, because anti-Ifnar1 mAb does not appreciably
cross the blood-brain barrier, the phenotype of the mutant
ZIKV-Dak-MA is more prominent in the brain. Notwithstanding
these data, ZIKV-Dak-MA still replicated slightly more effectively
than ZIKV-Dak in the CNS of Ifnar1/mice after direct intracra-
nial inoculation, suggesting there may be an additional pathway,
independent of type I IFN signaling, by which the adaptive muta-
tion functions; NS4B G18R could antagonize or co-opt other
host defense pathways, including type II or III IFN signaling or
autophagy in cells of the brain. Indeed, ZIKV NS4B reportedly
modulates Akt-mTOR signaling and autophagy induction (Liang
et al., 2016), and autophagy confers a proviral advantage for
ZIKV (Cao et al., 2017).
Most adult mouse models of ZIKV infection require eliminating
or inhibiting the mouse type I IFN response to achieve infection
and pathogenesis (reviewed in Morrison and Diamond, 2017).
Nonetheless, several immunocompetent mouse models of
ZIKV infection have been described, although each has limita-
tions. These include (1) peripheral infection of neonatal (<1-
week-old) WT mice (Lazear et al., 2016; Manangeeswaran
et al., 2016), which have immature immune responses; (2) direct
intrauterine injection of WT pregnant dams (Vermillion et al.,
2017), which bypasses trans-placental transmission; (3) direct
injection of fetal brains during pregnancy (Wu et al., 2016), which
bypasses the placenta entirely; and (4) administration of high-
dose ZIKV via an intravenous route to pregnant dams (Cugola
et al., 2016), which bypasses peripheral immune responses. To
overcome the lack of Stat2 antagonism, which limits ZIKV repli-
cation in the peripheral tissues likely due to sustained type I and
III IFN responses, we engineered a transgenic mouse that
replaced most of mouse Stat2 with human STAT2. This mouse
showed normal immune responses to poly(I:C), a stimulus that
activates IFN induction. ZIKV, especially the NS4B G18R adapt-
ed strain, was able to replicate, spread to the brain, cause
lethality in juvenile (3-week-old) hSTAT2 KI mice, and result in
trans-placental transmission and fetal infection in pregnant
dams. Of note, the pregnant dams themselves, despite vertically
transmitting ZIKV, did not sustain infection in the brain, which is(J–M) Eleven-week-old hSTAT2 KI or WT dams mated to hSTAT2 KI and WT
were harvested on E13.5. Viral burden in maternal serum (J), maternal spleen (
10 hSTAT2 KI dams, n = 36 WT and 32 hSTAT2 KI placentas and fetal heads,
and dotted lines denote the limit of detection of the assay.
See also Figures S4 and S5.characteristic of human infection. Thus, ZIKV infection in adult
hSTAT2 KI mice also did not recapitulate the extreme vulnera-
bility and lethality of Ifnar1/ (Lazear et al., 2016) or Stat2/
mice (Tripathi et al., 2017); this could reflect cell-extrinsic anti-
viral effects of IFN signaling in uninfected cells (as seen in our
single-cell RNA-seq data) or the lack of additional species-spe-
cific evasion mechanisms that are not accounted for by the
NS4B mutation (e.g., DENV antagonizes human, but not mouse,
STING; Aguirre et al., 2012). Alternatively, the absence of brain
infection in adult hSTAT2 KI mice could reflect the age-depen-
dent maturation of the blood-brain barrier and the tightening
effects of type I and III IFNs, both of which signal through Stat2
(Daniels et al., 2014, 2017), which would be absent in Ifnar1/
and Stat2/ mice.
In summary, we identified an adaptive mutation in ZIKV NS4B
that confers enhanced virulence in mice and NSCs for African
and American ZIKV strains. We applied single-cell RNA-seq
analysis in uninfected and ZIKV-infected NSCs to define unique
cell-intrinsic transcriptional signatures and used this information
to establish mechanistically how the adaptive NS4B mutation
enhanced infectivity and virulence. By combining the adapted
virus with transgenic mice that exchanged human and mouse
STAT2, which restricts ZIKV infection in a species-dependent
manner, we developed an immunocompetent model of ZIKV
infection and pathogenesis after peripheral inoculation that
more closely recapitulates features of human infection. This
immunocompetent small animal model of ZIKV infection may
prove a resource for determining mechanisms of pathogenesis,
defining correlates of innate and adaptive immune protection,
and evaluating countermeasures to limit disease.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals and Ethics
Wild-type (WT) C57BL/6 (000664) mice were purchased from Jackson Laboratory. Congenic Rag1-/-, Ifnar1-/-, Stat2-/- (Park et al.,
2000), and hSTAT2 KI C57BL/6 mice were bred in a specific-pathogen-free facility at Washington University or the Icahn School
of Medicine at Mount Sinai. 4 to 6 week-old mice, or 11 week old pregnant female mice were used. Littermates of the same sex
were randomly assigned to experimental groups. This study was carried out in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by theCell Host & Microbe 23, 672–685.e1–e6, May 9, 2018 e2
Institutional Animal Care andUseCommittee at theWashingtonUniversity School ofMedicine (Assurance number A3381-01). Animal
studies also were approved by the Institutional Animal Care and Use Committee of Icahn School of Medicine at Mount Sinai
(Assurance number A311-01). Virus inoculations were performed under anaesthesia that was induced and maintained with ketamine
hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
Cell Lines
Vero cells were cultured at 37C in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 5% fetal bovine serum (FBS) and
25 mM HEPES.
Primary Cell Cultures
NSCs were isolated from 4 to 6 week-old WT C57BL/6 mice. NSCs were cultured in Neurobasal media (Thermo Fisher) without
phenol red, supplemented with B27 without vitamin A (Thermo Fisher) and N-2 supplement (Thermo Fisher) at 37C in 5% CO2.
NSCs were plated at 105 cells in 2 ml of Neurobasal media per well in 6 well plates treated with matrigel (Corning, 08-774-552).
Viruses
ZIKV strain Dakar 41525 (Senegal, 1984, GenBank: KU955591) was provided by the World Reference center for Emerging Viruses
and Arboviruses (R. Tesh, University of Texas Medical Branch). ZIKV stocks were propagated in Vero cells, and cell supernatants
were harvested 66-72 h post inoculation. Virus stocks were titrated by focus forming assay (FFA) on Vero cells as previously
described (Lazear et al., 2016) and stored aliquoted at -80C.
METHOD DETAILS
Mouse Experiments
In some experiments, mice were treated with 2 mg of an Ifnar1-blocking antibody (MAR1-5A3, Leinco Technologies) by intraperito-
neal injection one-day before virus infection. Mice were inoculated with ZIKV by a subcutaneous (via footpad) route with 104 to 106
FFU PFU of ZIKV in a volume of 50 ml PBS or by an intracranial route with 104 FFU of ZIKV in a volume of 10 ml PBS. For survival
studies, mice were monitored for 21-45 days. For enhanced safety, all mouse infection experiments with ZIKV were performed under
A-BSL3 conditions.
hSTAT2 KI Mouse Generation
The hSTAT2 KI mouse line was generated commercially by TaconicArtemis Gmbh. The targeting vector was constructed using bac-
terial artificial chromosome clones C57BL/6J RPCIB-731 and human RPCIB-753, transfected into the TaconicArtemis C57BL/6N
Tac ES cell line, and selected with neomycin and puromycin. The integration in ES cells was confirmed by Southern blotting and
PCR. Germline pups were bred to C57BL/6-Tg(CAG-Flpe)2 Arte (Schaft et al., 2001) for removal of the neomycin and puromycin
cassettes, and the Flpe transgene was bred away by backcrossing. Mice were genotyped with primers CTGAGGTAGAATCACTTT
GACTTCC-5079-42 and aGATGGCTCAGAGGTTAAGAGC-5079-43, or GGCAAAGCCAAGACATAAACC-5080-46 and ACAGGTTC
CAGGCCATCAAG-5080-47 and PCR conditions: 94C 30 sec, 60C 30 sec, 72C 1 min. Western blotting for human STAT2 (Santa
Cruz sc-476) or mouse Stat2 (Cell signaling 4597) was performed on splenocytes isolated 24 h after intravenous injection of 100 mg of
poly(I:C).
IFN Responses in Mice
WT, hSTAT2 KI, and Stat2-/-mice were administered 50 mg of poly(I:C) (Invivogen, tlrl-pic) via an intranasal route in 50 ml of PBS, and
lungs were harvested 6 h later. Lungs were homogenized in RLT buffer (Qiagen RNAeasy kit), and total RNA was isolated from 200 ml
of tissue homogenate. RT-PCRwas performed as described (Tripathi et al., 2017). ISGs were detected with the following primer sets:
mouse Oas1a Forward 5’-ATGGAGCACGGACTCAGGA-3’ mouse Oas1a Rev 5’-TCACACACGACATTGACGGC-3’; mouse Ifnb1
Forward 5’-CAGCTCCAAGAAAGGACGAAC-3’ mouse Ifnb1 Reverse 5’-GGCAGTGTAACTCTTCTGCAT-3’; mouse Irf7
Forward 5’-GAGACTGGCTATTGGGGGAG-3’ mouse Irf7 Reverse 5’-GACCGAAATGCTTCCAGGG-3’; mouse 18s rRNA Forward
5’- GTAACCCGTTGAACCCCATT-3’ mouse 18s rRNA Reverse 5’-CCATCCAATCGGTAGTAGCG-3’
Viral Burden Measurements
ZIKV-infected mice were anesthetized with ketamine, blood was collected, and animals were perfused with at least 15 ml of PBS at
specified time points after infection. The spleen and brain were harvested, weighed, and homogenized by bead dissociation using a
MagNA Lyzer (Roche) in 1 ml of Dulbecco’s Modified Eagle’s Medium (DMEM) containing 2% fetal bovine serum (FBS). Blood was
allowed to clot at room temperature and serum was separated by centrifugation. Viral RNA was isolated using the RNeasy 96 Kit
(Qiagen) as described by the manufacturer. ZIKV RNA levels were determined by TaqMan one-step quantitative reverse transcrip-
tase PCR (qRT-PCR) as described previously (Govero et al., 2016). A published primer set (Govero et al., 2016) was used to detect
ZIKV RNA: Forward 5’-CCACCAATGTTCTCTTGCAGACATATTG-3’; Reverse 5’- TTCGGACAGCCGTTGTCCAACACAAG-3’; Probe
5’-/56-FAM/AGCCTACCT/ZEN/TGACAAGCAGTC/3IABkFQ/-3’ (Integrated DNA Technologies). For some samples, viral titer
was determined by plaque assay as described (Lazear et al., 2016). Briefly, brains were harvested, weighed, and homogenizede3 Cell Host & Microbe 23, 672–685.e1–e6, May 9, 2018
by bead dissociation using a MagNA Lyzer (Roche) in 1 ml of DMEM containing 2% FBS. Samples were clarified by centrifugation
(2,000x g at 4C for 10 min), diluted serially, and then added to Vero cell monolayers in 6 well plates. Cells were overlaid with 2% low
melting point agarose (Lonza) and 4 days later were fixed with 10% formaldehyde and stained with crystal violet for manual counting
on a lightbox.
NSC Isolation and Infection
NSCs were isolated from 4 to 6 week-old WT C57BL/6 mice. The subventricular zone of the brain was digested in 0.05% trypsin
(Invitrogen) for 30 min at 37C. Cells were resuspended after pipetting up and down twenty times. NSCs were cultured in Neurobasal
media (Thermo Fisher) without phenol red, supplemented with B27 without vitamin A (Thermo Fisher) and N-2 supplement (Thermo
Fisher) at 37C in 5% CO2. NSCs were plated at 10
5 cells in 2 ml of Neurobasal media per well in 6 well plates treated with matrigel
(Corning, 08-774-552) and inoculated with ZIKV at an MOI of 0.01 or 1. For some experiments, NSCs were pretreated with 25 mg/mL
of Ifanr1 blocking antibody (MAR-1 5A3), 3 or 10 U/mL of IFN-b (PBL Assay science, 12400-1) for 16 h before infection. Supernatants
were harvested andmediumwas replaced at indicated time points. Viral burden in the supernatant was determined by focus-forming
assay (FFA). NSCswere harvested at 96 h after infection, fixed in Foxp3/transcription factor staining buffer (eBioscience), and stained
with a combination of anti-ZIKV murine mAbs (ZIKV-2 and ZIKV-13) or only CHK-152 as an isotype control using 200 ng of mAb per
50 ml. Cells were then incubated with goat anti-mouse Alexa Fluor 647 antibody (Thermo Fisher Scientific) and analyzed on a
MACsQuant8 flow cytometer (Miltenyi Biotec).
IFN-b Production in NSCs during ZIKV Infection
NSCswere cultured in Neurobasal media without phenol red, supplemented with B27 without vitamin A and N-2 supplement at 37C
in 5% CO2. NSCs were plated at 10
5 cells in 2 mL of Neurobasal media per well in 6 well plates treated with matrigel and inoculated
with ZIKV at an MOI of 1. After 4 h, cells were washed three times in PBS, and media was replaced with 2 mL of fresh Neurobasal
media. At the indicated time points, supernatant was collected and Ifnb in the supernatant was measured using VeriKine Mouse Ifnb
ELISA (PBL Assay Science, 42400-1) according to the manufacturer’s protocol. In brief, 100 ul of supernatant was added to
precoated wells and incubated for 1 h at room temperature. Detection, development, and washing steps were performed as
described by the manufacturer’s protocol. OD450 was recorded using a Tristar LB 941 reader (Berthold Technologies). IFN-b con-
centration was determined by comparing OD450 values to a standard curve. Limit of detection (LOD) was determined by calculating
the mean and standard deviation (SD) of blank controls, and setting the LOD at three SDs above the mean of the blank controls.
Cell Viability Assay
Cell viability was measured using CellTiter-Glo reagents (Promega) according to the manufacturer’s protocol. Briefly, NSCs
were plated at 105 cells in 2 mL of Neurobasal media in 6 well plates treated with matrigel. Cells were inoculated with ZIKV at an
MOI of 1. Ninety-six hours after infection, 1.7 ml of media was removed and 300 ml of CellTiter-Glo reagent was added to each
well. Plates were incubated for 15 min at room temperature and luminescence was recorded using a Synergy H1 Hybrid Reader
(Bio-tek).
Next-Generation Sequencing of ZIKV
Preparation of sequencing libraries was performed as described (Miner et al., 2016). Briefly, RNA was extracted from the input or
passaged virus, reverse-transcribed into cDNA, and then amplified in eight segments using Q5 DNA polymerase (New England
Biolabs). DNA was fragmented using dsDNA fragmentase (New England Biolabs), and adapters and indexes were added to prepare
Illumina compatible libraries using the NEBNext Ultra II DNA library prep kit (New England Biolabs). Libraries were sequenced on an
Illumina Nextseq 500. The demultiplexed fastq files for the input were aligned to the ZIKV genome (Strain ArD_41519, Accession
HQ234501) to create a consensus sequence. The input consensus sequence was used as a reference file to assess mutations pre-
sent in the passaged virus. Variant calling was performed with LoFreq (Wilm et al., 2012) and consensus sequences were generated
with Geneious software. All sequences have been uploaded and will be published upon publication of a finalized manuscript.
ZIKV-Dak and ZIKV-Bzl Infectious Clones
We developed an infectious clone utilizing a published reverse genetics platform (Widman et al., 2017). We applied a unidirectional
quadripartite assembly method using asymmetric, nonpalindromic, naturally encoded restriction enzyme sites located near known
centers of toxicity for bacterial expression (Messer et al., 2012; Widman et al., 2017). Cleavage sites were located at nucleotide
positions 3064, 4451, and 7220 of the ZIKV-Dak (strain 41525) genome and resulted in four fragments for expression in
bacterial plasmids. Non-native modifications added to the consensus sequence included hepatitis D virus ribozyme following the
native 3’ untranslated region (UTR) as well as a T7 promotor upstream of the 5’-UTR for in vitro transcription. Site-directed
mutagenesis overlap PCR was performed to generate mutations at positions NS3 K339R and/or NS4B G18R in ZIKV-Dak WT
and ZIKV-Bzl WT clones (Widman et al., 2017). Screening was performed via Sanger sequencing to confirm mutagenesis as well
as genetic integrity of the rest of the fragment.
Bacterial cultures of MC1061 or Top10 competent E. coli cells containing the quadripartite wild-type or mutant fragments were
grown overnight at 27.6C in appropriate selection growth media. Plasmids were isolated and digested according to molecular
construction design, and ligated together overnight at 4C. After ligation, DNAwas precipitated via chloroform extraction and alcoholCell Host & Microbe 23, 672–685.e1–e6, May 9, 2018 e4
precipitation. The DNA pellet was resuspended in molecular grade water, and used as template for RNA transcription via T7
polymerase (Ambion). Reactions were incubated at 30C or 37C for 3-4 h and then electroporated into Vero cells. After 2-4 days,
depending on cytotoxicity, supernatant containing virus was collected and filtered through 0.22 mMfilters. After harvest and filtration,
viral RNAwas isolated (Qaigen Viral Mini RNA Kit), transcribed into cDNA via RT-PCR (Invitrogen), and sequenced via whole genomic
Sanger Sequencing to ensure identity. Infectious clone generated viral titers were comparable to the passaged natural isolates.
Single Cell RNA-Seq
NSCs were resuspended at 103 cells/mL in PBS containing 0.04% (w/v) BSA to minimize cell loss and aggregation. 17,500 cells
were partitioned into nanoliter-scale Gel Bead-In-EMulsions (GEMs) to achieve single cell resolution for a maximum of 10,000
individual cells per sample. Utilizing the v2 Chromium Single Cell 3’ Library Kit and Chromium instrument (10x Genomics), poly-ad-
enylated mRNA from an individual cell was tagged with a unique 16 basepair 10x barcode and 10 basepair Unique Molecular
Identifier. Full length cDNA was amplified to generate sufficient mass for library construction. Enzymatic fragmentation and size
selection were used to optimize the cDNA amplicon size (400 basepair) for the library. The final library was sequence-ready and
contained four unique sample indexes. The concentration of the 10x single cell library was determined through qPCR (Kapa Bio-
systems). The libraries were normalized, pooled, and sequencedwith a custom recipe (26-8-98) on theHiSeq4000 platform (Illumina).
Five single cell libraries were sequenced across an entire HiSeq4000 flow cell targeting 45,000 reads per cell.
Alignment, Barcode Assignment and Unique Molecular Identifier (UMI) Counting
The Cell Ranger Single-Cell Software Suite (version 2.0.2) (https://support.10xgenomics.com/single-cell-gene-expression/software/
pipelines/latest/what-is-cell-ranger) was used to perform sample demultiplexing, barcode processing, and single-cell 3’ counting.
Cellranger mkfastq was used to demultiplex raw base call files from the HiSeq4000 sequencer into sample-specific fastq files. Files
was demultiplexed with 98%+ perfect barcode match, and 74%+ q30 reads. Subsequently, fastq files for each sample were
processed with cellranger counts to align reads to the mm10 mouse genome. The default estimated cell count value of 10,000
was used for this experiment. Samples were subsampled to have equal numbers of confidently mapped reads per cell. A separate
run of cellranger count was performed to align reads to the ZIKV Dakar 41525 genome (GenBank: HQ234501.1) to obtain viral UMI
counts.
Preprocessing Analysis with Seurat Package
For the analysis, the Seurat package (version 2.1) (Butler and Satija, 2017) was used. Cell Ranger filtered genes by barcode expres-
sion matrices were used as analysis inputs. Samples were pooled together using the AddSample function. The fraction of mitochon-
drial genes was calculated for every cell, and cells with a mitochondrial fraction > 5% were filtered out. Two sources of unwanted
variation:UMI counts and fraction of mitochondrial reads – were removed with RegressOut function. Expression measurements
for each cell were normalized by total expression and then scaled to 10,000, after that log normalization was performed. Viral
UMI counts were analyzed separately from reads mapped to the mm10 genome. Viral UMI counts were normalized to the total
UMI count within the cell (both viral and non-viral) and then scaled to 10,000, and then log-normalization was performed. ZIKV-
infected cells were defined arbitrarily as having greater than 0.03% of viral transcripts relative to total cellular transcripts since the
background read level in naive, uninfected cells was less than 0.02% of total cellular transcripts.
Dimensionality Reduction and Clustering
The most variable genes were detected using FindVariableGenes function. PCA was run only using these genes. Cells are repre-
sentedwith t-SNE (t-distributed Stochastic Neighbor Embedding) plots. We applied RunTSNE function to normalized data, using first
10 PCA components. For clustering, we used function FindClusters that implements SNN (shared nearest neighbor) modularity
optimization based clustering algorithm on 10 PCA components with a resolution of 0.2. Seven clusters were detected, one of which
contained poorly covered cells (lower number of UMIs and detected genes); this cluster was excluded from further analysis.
Identification of Cluster-Specific Genes and Marker-Based Classification
To identify marker genes, FindAllMarkers function was used with likelihood-ratio test for single cell gene expression. For each cluster
only genes that were expressed inmore than 25%of cells with at least 0.25-fold differencewere considered. To characterize clusters,
we used the followingmarkers. NSCs: Id3,Clu,Rpl32, Egfr,Dlx2,Nes, Sox2,Gfap, andRbfox3; Cell cycle:Cdk4,Cdk1, Tipin,Cenpa,
Pcna, Mki67, Top2a, and Mcm5; ISGs: Ddx58, Ifih1, Rsad2, Isg15, Ccl5, and Cxcl10; and Viral infection: ZIKV RNA. NSC and cell
cycle markers were selected based on published data (Dulken et al., 2017; Kowalczyk et al., 2015).
Single Cell RNA-Seq Differential Expression
To obtain differential expression between infected cells for 24 or 48 h with ZIKV-Dak WT vs ZIKV-Dak-MA, a MAST test was
performed and P value adjustment was performed using a Bonferroni correction (Finak et al., 2015).
qRT-PCR of IFN-b mRNA
NSCs were cultured in Neurobasal media without phenol red, supplemented with B27 without vitamin A and N-2 supplement at 37C
in 5% CO2. NSCs were plated at 10
5 cells in 2 ml of Neurobasal media per well in 6 well plates treated with matrigel and inoculatede5 Cell Host & Microbe 23, 672–685.e1–e6, May 9, 2018
with ZIKV at an MOI of 1. After 4 h, cells were washed three times in PBS, and media was replaced with 2 ml of fresh Neurobasal
media. At specified time points, supernatant was removed and cells were lysed in 500 mL of RLT. RNAwas extracted using anRNeasy
Mini Kit (Qiagen, 74104) and on-column DNase digestion was performed using RNase-Free DNase set (Qiagen, 79254) following the
manufacturers protocol. 18S ribosomal and Ifnb, were determined by Taqman one-step quantitative reverse transcriptase PCR
(qRT-PCR). 18S ribosomal RNA was measured using an Eukaryotic 18S rRNA endogenous control (Thermo Fisher Scientific,
4319413E), and IfnbmRNA levels were determined using predesigned qPCR assay (IDT, Mm.PT.58.30132453.g). Gene expression
was normalized to the 18S ribosomal housekeeping gene, and the 2-DDCt method was used to calculate fold expression over mock.
Sequence Alignment for ZIKV and Related Flaviviruses
Sequences for ZIKV strains and flavivirus strains were obtained from the NIAID Virus Pathogen Database and Analysis Resource
(ViPR) (Pickett et al., 2012) through the website https://www.viprbrc.org/brc/vipr_genome_search.spg?method=ShowClean
Search&decorator=flavi. Sequences were aligned using Geneius (http://www.geneious.com, version 11.0.4; Kearse et al., 2012)
and MUSCLE sequence alignment algorithm. ZIKV-Dak was used as the reference sequence to determine the position of
amino acids.
Sanger Sequencing of Passaged ZIKV Isolates
RNA from viral tissues was isolated using RNeasy Mini Kit (Qiagen, 74104) as described in the manufactures protocol. cDNA was
generated using SuperScript III first-strand synthesis supermix (Thermo Fisher Scientific, 18080400), and cDNA was amplified using
Phusion High Fidelity PCR Master Mix (New England Biolabs, M0531S). Primer set used to amplify cDNA ZIKV-Dakar 3500-
7000 amplifying primer: 5’- AGA AAG GAA CCA GAG AGC AAC TTA-3’ ZIKV-Dakar 7100-3500 amplifying primer: 5’-
GTGGTTACCGCATGTTGG-3’. Sanger sequencing was performed by Genewiz (https://www.genewiz.com/en/Public/Services/
Sanger-Sequencing), and sequences were aligned by the ClustaW Method using DNAstar Megalign (https://www.dnastar.com/
t-megalign.aspx). Primer set used to sequence regions of interest ZIKV-Dakar 5500 sequencing primer: 5’-TGCACGAGGATATATAT
CAACAAGGG-3’ ZIKV-Dakar 6500 sequencing primer: 5’- TTG CCA GGA CAC ATG ACA GAG-3’.
Viral RNA In Situ Hybridization
RNA ISH was performed using RNAscope 2.5 HD (Brown) (Advanced Cell Diagnostics) according to the manufacturer’s instructions.
PFA-fixed, paraffin-embedded tissue sections were deparaffinized by incubating for 60 min at 60C and endogenous peroxidases
were quenched with H2O2 for 10min at room temperature. Slides were then boiled for 15min in RNAscope Target Retrieval Reagents
and incubated for 30 min in RNAscope Protease Plus reagent prior to addition of a custom-designed ZIKV RNA probe (Advanced
Cell Diagnostics, catalog #467771). Sections were counterstained with Gill’s hematoxylin and visualized by brightfield microscopy.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments are found in the corresponding Figure Legends. No statistical methods were used to predetermine
sample size a priori and investigators were not blinded to allocation during experiments and outcome assessment. Survival
experiments were analyzed by Kaplan-Meier survival analysis and the log-rank test. Viral burden in tissues was analyzed by the
Mann-Whitney test. Viral growth kinetics was analyzed by two-way ANOVA with multiple comparison corrections as needed. The
percentage of infected NSCs was analyzed by a student t-test. IFN-b production was analyzed by a student t-test. ISGs expression
in infected NSCs was analyzed by a MAST test. Differential expression of viral RNA was analyzed by Mann-Whitney test. Cell
viability data was analyzed by a one-way ANOVA. Statistical analyses were conducted with Prism 6 software (Graphpad). P values
of < 0.05 were considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
The single-cell RNAseq data can be accessed at Gene Expression Omnibus (GEO: GSE112711). The next-generation sequencing
of ZIKV-Dak-MA has been deposited in the SRA database as SRA: PRJNA413540. Consensus sequences for ZIKV-Dak
(GenBank: MG758785) and ZIKV-Dak-MA (GenBank: MG758786) have been uploaded in GenBank.Cell Host & Microbe 23, 672–685.e1–e6, May 9, 2018 e6
